This clinical trial is focused on studying a condition called Myelodysplastic Syndromes (MDS), which is a group of disorders caused by poorly formed or dysfunctional blood cells. The study specifically looks at patients with lower risk MDS who have anemia, a condition where there is a lack of healthy red blood cells, but who are not dependent on red blood cell transfusions. The treatment being tested is called Epoetin Alfa, which is a medication used to help the body produce more red blood cells.
The purpose of the study is to compare the effects of starting Epoetin Alfa treatment early versus starting it later in patients with lower risk MDS and anemia. Participants will be randomly assigned to receive the treatment either at the beginning of the study or at a later stage when their condition reaches a certain point. The study will observe how long it takes for patients to become dependent on red blood cell transfusions in both groups.
Throughout the study, participants will receive regular injections of Epoetin Alfa and will be monitored to see how their condition progresses. The study aims to provide valuable information on the best timing for starting treatment with Epoetin Alfa in patients with lower risk MDS and anemia, potentially improving their quality of life and health outcomes.
France 
